Salix gains new rights as rifaximin deal with Alfa restructured
This article was originally published in Scrip
Salix Pharmaceuticals is again seeking new lines of revenue from its top-selling product, Xifaxan (rifaximin) for traveller's diarrhoea and hepatic encephalopathy, most recently by renegotiating with Alfa Wasserman Salix's North American rights to rifaximin to include an extended intestinal release (EIR) formulation in gastrointestinal and respiratory indications, including Crohn's disease, for $10 million upfront.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.